Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Veloxis Announces the Total Number of Shares and Voting Rights


Posted on: 30 Sep 16

Company Announcement no. 22/2016 

 

To: NASDAQ OMX Copenhagen A/S                        Copenhagen, Denmark, 30 September 2016

   

Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 September 2016

Veloxis Pharmaceuticals A/S announces in accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, the total number of shares and voting rights in the company at the end of a calendar month in which changes to the share capital have occurred.  

With reference to Company Announcements no. 20/2016 dated 6 September 2016 and no. 21/2016 dated 20 September 2016 informing of an increase in the share capital and the voting rights after exercise of employee warrants, the table below provides the total number of shares and voting rights in Veloxis as of 30 September 2016.

 

Date Total number of shares
(nominal value of DKK 0.10 each)
Share capital
(nominal value in DKK)
Total number of votes
30 September 2016 1,701,873,881 170,187,388.10 1,701,873,881

    

For more information, please contact:

Craig A. Collard           

President & CEO                      

Phone: +1 919 524 4317                    

Email: cac@veloxis.com                       

    

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA and maintains a second corporate office in Edison, New Jersey, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.

 

GlobeNewswire
globenewswire.com

Last updated on: 03/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.